Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia
Article first published online: 7 JUL 2014
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians
Internal Medicine Journal
Volume 44, Issue 7, pages 697–699, July 2014
How to Cite
Jolliffe, E. and Romeril, K. (2014), Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia. Internal Medicine Journal, 44: 697–699. doi: 10.1111/imj.12468
Conflict of interest: None.
- Issue published online: 7 JUL 2014
- Article first published online: 7 JUL 2014
- Manuscript Accepted: 3 APR 2014
- Manuscript Received: 17 SEP 2013
- thrombopoeitin receptor agonist;
- immune thrombocytopenia;
- chronic lymphocytic leukaemia
Autoimmune manifestations are a common occurrence with chronic lymphocytic leukaemia (CLL). We describe a case of CLL-associated immune thrombocytopenia (ITP) that had a loss of response to standard treatment for ITP. The thrombopoeitin receptor agonist, eltrombopag, was successfully used preoperatively to increase the platelet count to a safer level, in this instance to facilitate laparoscopic splenectomy.